Clinical Trials on Hypophosphatemia in Canada

Total 28 results

Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

Korea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Inozyme Pharma

Recruiting

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

United States, United Kingdom, Canada
Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.

Active, not recruiting

X-linked Hypophosphatemia Disease Monitoring Program

X-linked Hypophosphatemia | Hypophosphatemic Rickets

United States, Brazil, Argentina, Canada, Chile, Colombia
Kyowa Kirin Pharmaceutical Development Ltd

Active, not recruiting

Registry for Patients With X-Linked Hypophosphatemia (XLH Registry)

X-Linked Hypophosphatemia

Spain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Canada, Japan, France, Denmark
Inozyme Pharma

Recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, United Kingdom, Canada, France, Germany
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Alexion Pharmaceuticals

Completed

Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Alexion Pharmaceuticals

Completed

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Alexion Pharmaceuticals

Completed

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada, United Arab Emirates, United Kingdom
Alexion Pharmaceuticals

Completed

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
Alexion

Enrolling by invitation

Registry of Patients With Hypophosphatasia

Hypophosphatasia (HPP)

France, Poland, United Kingdom, Germany, Spain, Saudi Arabia, United States, Canada, Russian Federation, Australia, Italy
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis (SBR759)

Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Germany, United Kingdom, Italy, Belgium, Sweden, Canada, United States, Australia, Finland, France, Norway, Puerto Rico, Switzerland
Alexion Pharmaceuticals

Completed

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

United States, Japan, Italy, Germany, Turkey, India, Australia, United Kingdom, Argentina, France, Canada
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Israel, Poland, Turkey, Brazil, Thailand, United Kingdom, Canada, Slovakia, Czechia
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (MULBERRY)

Hypophosphatasia

United States, Taiwan, Thailand, Vietnam, United Kingdom, Korea, Republic of, Israel, Italy, Australia, Turkey, France, Poland, Germany, Spain, Belgium, China, Canada, Brazil, Argentina, Mexico
Mitsubishi Tanabe Pharma Corporation

Completed

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Canada
USRC Kidney Research
Akebia Therapeutics Inc.

Completed

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)

Renal Insufficiency | Hyperphosphatemia | Anemia, Iron Deficiency

United States
Ineos Healthcare Limited

Terminated

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

Chronic Kidney Failure

United States, Canada, Australia, New Zealand, Brazil, France, Germany, Malta, Poland, South Africa, Spain
Shire

Completed

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

Hyperphosphatemia

United States
Amgen

Completed

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Hyperparathyroidism | End Stage Renal Disease | Chronic Kidney Disease | Kidney Transplantation | Chronic Renal Failure | Hypophosphatemia | Kidney Disease | Chronic Allograft Nephropathy | Disordered Mineral Metabolism | Post Renal Transplantation

United States, Canada, France, Italy, Belgium, Switzerland, Spain, Australia, Germany, Austria, Poland
The University of Queensland
National Health and Medical Research Council, Australia; Cambridge University... and other collaborators

Recruiting

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) (PHOSPHATE)

Kidney Failure, Chronic | Hyperphosphatemia

Canada, United Kingdom, Australia, Brazil, New Zealand
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada

Clinical Trials on Hypophosphatemia in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations